Author Correction: A biallelic multiple nucleotide length polymorphism explains functional causality at 5p15.33 prostate cancer risk locus.

Autor: Spisak S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Tisza V; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Computational Health Informatics Program (CHIP) Boston Children's Hospital Harvard Medical School, Boston, MA, 02215, USA.; Institute of Enzymology, Research Centre for Natural Sciences, Budapest, 1117, Hungary., Nuzzo PV; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Department of Internal Medicine, School of Medicine, University of Genoa, Genoa, Lgo R. Benzi 10, 16132, Italy., Seo JH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Pataki B; Department of Physics of Complex Systems, ELTE Eötvös Loránd University, Pázmány P. s. 1A, Budapest, 1117, Hungary., Ribli D; Department of Physics of Complex Systems, ELTE Eötvös Loránd University, Pázmány P. s. 1A, Budapest, 1117, Hungary., Sztupinszki Z; Computational Health Informatics Program (CHIP) Boston Children's Hospital Harvard Medical School, Boston, MA, 02215, USA., Bell C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Rohanizadegan M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Stillman DR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Alaiwi SA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Bartels AH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Papp M; Institute of Enzymology, Research Centre for Natural Sciences, Budapest, 1117, Hungary.; Centre for Bioinformatics, University of Veterinary Medicine, Istvan str. 2, Budapest, 1078, Hungary., Shetty A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Division of Genetics, Brigham & Women's Hospital, Boston, MA, USA., Abbasi F; Women's Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA., Lin X; Women's Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA., Lawrenson K; Women's Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.; Center for Bioinformatics and Functional Genomics, Department of Biomedical Science, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA., Gayther SA; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.; Center for Bioinformatics and Functional Genomics, Department of Biomedical Science, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA., Pomerantz M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Baca S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; The Eli and Edythe L. Broad Institute, Cambridge, MA, 02142, USA., Solymosi N; Department of Physics of Complex Systems, ELTE Eötvös Loránd University, Pázmány P. s. 1A, Budapest, 1117, Hungary., Csabai I; Department of Physics of Complex Systems, ELTE Eötvös Loránd University, Pázmány P. s. 1A, Budapest, 1117, Hungary., Szallasi Z; Computational Health Informatics Program (CHIP) Boston Children's Hospital Harvard Medical School, Boston, MA, 02215, USA.; Department of Bioinformatics, Forensic and Insurance Medicine Semmelweis University, Budapest, Hungary.; Danish Cancer Society Research Center, Strandboulevarden 49, 2100, Copenhagen, Denmark.; National Korányi Institute of Pulmonology, Budapest, 1112, Hungary., Gusev A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Division of Genetics, Brigham & Women's Hospital, Boston, MA, USA.; The Eli and Edythe L. Broad Institute, Cambridge, MA, 02142, USA., Freedman ML; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. matthew_freedman@dfci.harvard.edu.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. matthew_freedman@dfci.harvard.edu.; The Eli and Edythe L. Broad Institute, Cambridge, MA, 02142, USA. matthew_freedman@dfci.harvard.edu.

Publikováno v: Nature communications [Nat Commun] 2023 Oct 19; Vol. 14 (1), pp. 6623. Date of Electronic Publication: 2023 Oct 19.